tbuckley/cabot-search huggingface dataset:
Effect of cellular vaccination of prostate cancer patients on IgG responses to peptide epitopes predicted from prostate tumor–associated autoantigens.
Authors: G. P. Hemstreet, V. M. Pisarev, C. A. Enke, R. J. Hauke, G. R. Rossi, L. Tennant, W. J. Ramsey, N. N. Vahanian, C. J. Link
Journal: Journal of Clinical Oncology (2011)

2558 Background: Tumor cell-based vaccines against prostate cancer (PC) represent a minimally toxic approach to treat the disease and prevent recurrence. Pre-clinical studies in rodent models of cancers have demonstrated the antitumor effectiveness of a vaccine composed of tumor cells transduced with the α-1,3-galactosyltransferase gene encoding the αGal epitope. We have completed a Phase I study for safety and feasibility of a prostate vaccine composed of two irradiated human PC cell lines engineered to express membrane–associated αGal epitopes (NLG-11928 NewLink Genetics, Inc.) The primary goals of this dose escalation study were to determine safety and vaccine-induced humoral immune responses to autoantigens frequently overexpressed in human prostate tumors. Methods: Eight patients received up to 12 biweekly vaccinations with NLG-11928 Plasma samples were collected from 8 patients with AJCC stage IV, Any T, Any N, M1, ECOG PS < 2, at least one prior hormonal treatment and < 3 prior chemotherapies, adequate bone marrow and organ function, and albumin >3.0 g/dl, Median age 70 (range 53-85). Specific IgG in plasma was determined by direct ELISA to 50 synthetic peptides representative of proteins commonly overexpressed in prostate tumors. Results: Median survival was 25.1 months (range 5 - 60 months) with one treated patient remaining alive at 60 months with stable PSA and bone metastasis since 2007. NLG-11928 induced IgG responses to synthetic peptides in a dose dependent manner. In 5 of 8 patients IgG responses were seen against at least one synthetic peptide predicted from PSMA, hepsin, EZH2, prostein, PARIS-1, GRP78, survivin, and SOX2. Furthermore, in 3 of these 5 patients, reactivity against a total of 19 synthetic peptide fragments was observed. Conclusions: Vaccination with NLG-11928 induces dose-dependent IgG responses to epitopes from autoantigens frequently overexpressed in PC. Some of these proteins (PSMA, hepsin) belong to the extracellular molecules participating in malignant cell invasion. NLG-11928 may represent a viable approach to induce immune response against tumor cells bearing these proteins and provide a clinical benefit.
Interventions to increase referral to and uptake of Pulmonary Rehabilitation programmes for people with Chronic Obstructive Pulmonary Disease (COPD): A systematic review
Authors: F. Early, I. Wellwood, I. Kuhn, T. Dickerson, Ward, J. Brimicombe, C. Deaton, J. Fuld
Journal: Thorax (2016)

Introduction and objectives  Pulmonary Rehabilitation (PR) reduces the number and duration of hospital admissions, readmissions and improves health-related quality of life, e.g. breathlessness and fatigue, in patients with COPD. Despite evidence, guidelines and quality standards, PR is significantly underutilised with under-referral (15% of normative need) and limited uptake (  We aimed to address the research question: How effective are interventions to improve referral to and uptake of exercise-based pulmonary rehabilitation programmes in patients with COPD when compared to standard care or no intervention?  Methods  Systematic review following recognised methods, including all published observational, interventional, qualitative and quantitative studies of interventions specifically intended to increase levels of referral and/or uptake of pulmonary rehabilitation in patients with COPD.  Exclusion criteria: individual case studies, conference abstracts and opinion pieces. No date or language restrictions.  Search terms included: ‘pulmonary rehabilitation’ AND ‘referral’ OR ‘uptake’ applied to MEDLINE, EMBASE, CINAHL, PsychINFO, ASSIA, BNI, Web of Science and Cochrane Library from inception to June 2016 supplemented by review of reference lists and citation search. Titles, abstracts and full papers were reviewed independently, quality appraised (using Cochrane Collaboration’s tool for RCTs and ROBINS-I, AMSTAR) and entered into summary tables. The protocol was registered (PROSPERO) and reported according to PRISMA guidelines.  Results  We screened 3217 references, from which 7 papers including 6345 patients and 22 clinicians met inclusion criteria. Most studies (n = 5) were UK based.  Designs, interventions and scope of studies were diverse with interventions often part of multifaceted evidence based management of COPD. Examples included computer based prompts at practice nurse review, patient information, financial incentives. Most studies (n = 5) reported improvements in referral or uptake of PR (range 0% – 25% increase), however most had methodological limitations with risk of bias. Due to heterogeneity, studies were not considered combinable and meta-analysis was inappropriate.  Conclusions  There is limited evidence for the efficacy of interventions to increase referral and uptake of PR. Existing studies are diverse and further testing using robust methods in various populations and settings is required to optimise access to PR.
Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes
Authors: Aristoteles Giagounidis, Azra Raza, Alan F. List, Pierre Fenaux, Bouchra Benettaib, Benton Brown, Jim Zhong, Nancy Brandenburg, Ghulam J. Mufti
Journal: Blood (2011)
MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer
Authors: Kenichi Suda, Leslie Rozeboom, Christopher Rivard, Hui Yu, Mary Ann Melnick, Trista Hinz, Kim Ellison, Daniel Chan, Katerina Politi, Lynn Heasley, Tetsuya Mitsudomi, Fred R. Hirsch
Journal: Journal of Thoracic Oncology (2017)
P3.04-022 Unexpected Residual Carcinoma in the Bronchial Stump after Surgery for Lung Cancer
Authors: Yohei Kameda, Michihiko Tajiri, Junya Morita, Kimihisa Shiino, Yoko Kojima, Hiromasa Arai, Koji Okudela, Yoichi Kameda, Munetaka Masuda
Journal: Journal of Thoracic Oncology (2017)
P2.03b-076 MAP2K1 Mutations in NSCLC: Clinical Presentation and Co-Occurrence of Additional Genetic Aberrations
Authors: Alessandra Holzem, Lucia Nogova, Michaela Ihle, Claudia Wömpner, Elisabeth Bitter, Sebastian Michels, Alessandra Lamanna, Britt-Marie Christensen, Rieke Fischer, Britta Kaminsky, Jens Kern, Ullrich Graeven, Anna Kostenko, Sabine Merkelbach-Bruse, Reinhard Büttner, Matthias Scheffler, Jürgen Wolf
Journal: Journal of Thoracic Oncology (2017)
Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.
Authors: Roberto Latagliata, Angela Rago, Antonio Spadea, Cristina Santoro, Ida Carmosino, Massimo Breccia, Laura Napoleone, Angelo Fama, Francesca Biondo, Paola Volpicelli, Maria Concetta Petti, Giuliana Alimena, Maria Gabriella Mazzucconi
Journal: Blood (2007)
P09.05 Patterns of care and outcome in low-grade gliomas diagnosed during 2000–2010 in Spain
Authors: C. Izquierdo
Journal: Neuro-Oncology (2016)

1) Evaluate the routine clinical treatment and the outcome of patients with low grade gliomas (LGG) in Spain to determine the most extended patterns of care 2) Assess prognostic factors related with progression, malignization and survival 3) Analyze the main features of LGG in the elderly population (≥60 years-old). Databases from 28 Spanish hospitals were reviewed retrospectively from 2000 to 2010. Information regarding demographic, clinical, radiologic, therapeutic and surgery variables were extracted. Survival and time-dependent variables were estimated using the Kaplan-Meier method. Exhaustive Chi-squared Automatic Detection (CHAID) was used to create a growing tree analysis with the aim to identify the subsets of patients with different time-related variables. Six hundred forty-nine patients were reviewed, 72 patients (11.1%) were older than 60 years old. The mean age at presentation was 41.6 years (range 18.5 to 77.9). Most patients (70.8%, n=455) presented with seizures, 8% (n=52) were pharmacoresistant. Surgical resection was performed in most patients (n=523, 80.6%) whereas 19.4% (n=126) of patients were biopsied. One third of tumors located in eloquent areas (n=87/270) were operated using intraoperative neurophysiologic techniques of monitoring. After surgery more than half of the patients did not received treatment (n=389, 60%). Radiotherapy (RT) was subsequently administered in 240 (37%) patients, and chemotherapy (alone or with RT) in 67 patients (10.3%). The median time to progression, to anaplastic transformation and the overall survival (OS) were 4.4 years (0.1–15.2), 4.2 years (0.3–12.4) and 6.1 years (0–15.2). Recursive Partitioning Analysis (CHAID method) using Pignatti Index (PI) and other clinical, radiological and treatment variables found 4 prognostic nodes associated to the OS. Node 1 [PI 0–1 + pre-operative non-contrast enhancement (CE)]; Node 2 [PI 0–1+ CE]; Node 3 [PI 2–5+ tumour resection] and Node 4 [PI 2–5 + biopsy]. Cox-regression analysis revealed that these 4 nodes were independent variables associated to the OS. In the elderly population, the OS was significantly worse than younger patients, even if the analysis was stratified by the prognostic PI (p<0.001). Independently, the multivariate analysis suggested that surgical resection (HR:4.33;CI95%:1.54–12.2;p=0.006), and oncological complementary treatment (HR:3.034;CI95%:0.97–9.43;p=0.056) presented favorable impact in the OS of elderly population. Despite most LGG were located in eloquent areas, only in 32% of cases intraoperative monitoring was performed. The RPA classification arises as a new useful prognostic tool of OS that complements PI, although independent validation is needed. Elderly population presents a worse outcome, however complementary treatment should be proposed in order to improve their survival.
P3.02c-065 Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients
Authors: Laura Mezquita, Melinda Charrier, Edouard Auclin, Maria Gion, Jordi Remon, David Planchard, Louise Dupraz, Jihene Lahmar, Annas Gazzah, Nathalie Chaput, Benjamin Besse
Journal: Journal of Thoracic Oncology (2017)
P1.06-046 Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real-Life Multicenter Study
Authors: Tindara Franchina, Silvia Novello, Alessandro Russo, Martina Gianetta, Enrica Capelletto, Domenico Galetta, Annamaria Catino, Maria Rita Migliorino, Serena Ricciardi, Floriana Morgillo, Carminia Maria Della Corte, Danilo Rocco, Hector Soto Parra, Antonio Russo, Francesca Ambrosio, Veronica Franchina, Vincenzo Adamo
Journal: Journal of Thoracic Oncology (2017)
Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to SynapticDeficits in Fragile X Syndrome (vol 87, pg 382, 2015)
Authors: Emanuela Pasciuto, Tariq Ahmed, Tina Wahle, Fabrizio Gardoni, Laura D'Andrea, Laura Pacini, Sebastien Jacquemont, Flora Tassone, Detlef Balschun, Carlos G Dotti, Zsuzsanna Callaerts-Vegh, Rudi D'Hooge, Ulrike C Muller, Monica Di Luca, Bart De Strooper, Claudia Bagni
Journal: Neuron (2015)
Efficient Vaccination of Follicular Lymphoma (FL) Patients with Multiple Intradermal (ID) and Intravenous (IV) Administrations of Mature Dendritic Cells (DC) Loaded with Tumor Cell Lysate Ex Vivo.
Authors: Jean-Francois Rossi, Marion Baudard, Anne-Marie Conge, Frédéric Comte, Valérie Costes, Jean-Luc Veyrunes, Philippe Quittet, Valérie Rouillé, Catherine Barjot, Bernard Klein
Journal: Blood (2005)
Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling
Authors: Isabelle Melki, Yoann Rose, Carolina Uggenti, Lien Van Eyck, Marie-Louise Frémond, Naoki Kitabayashi, Gillian I. Rice, Emma M. Jenkinson, Anaïs Boulai, Nadia Jeremiah, Marco Gattorno, Sefano Volpi, Olivero Sacco, Suzanne W.J. Terheggen-Lagro, Harm A.W.M. Tiddens, Isabelle Meyts, Marie-Anne Morren, Petra De Haes, Carine Wouters, Eric Legius, Anniek Corveleyn, Frederic Rieux-Laucat, Christine Bodemer, Isabelle Callebaut, Mathieu P. Rodero, Yanick J. Crow
Journal: Journal of Allergy and Clinical Immunology (2017)
P3.02b-112 Feasibility of Re-Biopsy in Patients with Non-Small Cell Lung Cancer after Failure of Epidermal Growth Factor Receptor Targeted Therapy
Authors: Yoo-Duk Choi, Tae-Ok Kim, Hyeong-Won Seo, Sung Ahn, Jin-Sun Jang, Cheol-Kyu Park, Young-Chul Kim, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Mee-Sun Yoon, Sung-Ja Ahn, Hyun-Ju Seon, Seong Young Kwon, In-Jae Oh
Journal: Journal of Thoracic Oncology (2017)
Characteristics and Outcome of Adolescents with Acute Lymphoblastic Leukemia (ALL) Differ from Young Children in the B-Cell Lineage but Not in the T-Cell Lineage: Experience of the ALL Israeli National Studies (INS).
Authors: Ronit Elhasid, Gali Avrahami, Aya Abramov, Dina Attias, Ami Ballin, Bella Bielorai, Yoav Burstein, Herzel Gavriel, Joseph Kapelushnik, Hagit Miskin, Dalia Sthoeger, Michael Weintraub, Jerry Stein, Isaac Yaniv, Amos Toren, Myriam Ben Arush, Ronit Nirel, Shai Izraeli, B. Stark
Journal: Blood (2008)
Superagonistic Anti-CD28 Antibody TGN1412 as a Potential Immunotherapeutic for the Treatment of B Cell Chronic Lymphocytic Leukemia.
Authors: Chia-Huey Lin, Thomas Kerkau, Christine Guntermann, Martin Trischler, Niklas Beyersdorf, Yvonne Scheuring, Hans-Peter Tony, Christian Kneitz, Martin Wilhelm, Peter Mueller, Thomas Huenig, Thomas Hanke
Journal: Blood (2004)
Abstract A41: Development of a risk analysis model for triple-negative breast cancer stages and treatment of African American women
Authors: Rupak Chowdhury, Shami Nandy, Berhanu Tameru
Journal: Clinical Cancer Research (2017)

Abstract The main object of this study is to assess how different stages of triple-negative breast cancer (TNBC) influences treatment of triple negative breast cancer patient. The data was gathered from Alabama Department of Public Health. We developed a probabilistic pathway scenario tree based on the knowledge from the comprehensive literature review and organized the variables into twelve major parameter categories. We performed Monte Carlo simulations with the software @Risk 5.7 (Palisade Corporation) for the quantitative risk assessment to capture the uncertainty for the treatment of triple negative breast cancer and different stages of TNBC. The likelihood (LH) of having one of the treatments for Stage IV TNBC, Surgery and or Chemotherapy (CT) or none gave that the person is (African American women) AAW older than 50, TNBC ranges from a min. of 1.62 × 10−3 to a max. of 2.35 × 10−2 with the mean and standard deviation of 8.28 × 10−3 and 3.141 × 10−3 respectively. The LH of having one of the treatments for stage 1&amp;2 of triple negative breast cancer, Surgery and or CT or none gave that the person is AAW older than 50, TNBC ranges from 1.78 × 10−5 to 1.053 × 10−1 with the mean and standard deviation of 2.74 × 10−2 and 2.06 × 10−2 respectively. However, there are no standard guidelines for Triple negative breast cancer patients, our study suggests that stage 1&amp;2 triple negative breast cancer patients are most likely to be treated with either chemotherapy or surgery and stage 3, 4 triple negative breast cancer patient are most likely to be treated with combined surgery and chemotherapy. Note: This abstract was not presented at the conference. Citation Format: Rupak Chowdhury, Shami Nandy, Berhanu Tameru. Development of a risk analysis model for triple-negative breast cancer stages and treatment of African American women. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A41.
Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy In Stage I/II Extranodal NK/T-Cell Lymphoma of Nasal Cavity/Nasopharynx
Authors: Seok Jin Kim, Hyeon-Seok Eom, Jin Seok Kim, Jae-Yong Kwak, Deok-Hwan Yang, Sung-Kyu Park, Jong Ho Won, Jae Hoon Lee, Cheolwon Suh, Won Seog Kim
Journal: Blood (2010)
P1.02-036 An EGFR Tyrosine Kinase Inhibitor Sensitive Patient-Derived Lung Cancer Xenograft Model without Classical Sensitizing Mutations
Authors: Hirotsugu Notsuda, Ming Li, Christine Ng, Ni Liu, Vibha Raghavan, Chang-Qi Zhu, Nhu-An Pham, Geoffrey Liu, Frances Shepherd, Ming Tsao
Journal: Journal of Thoracic Oncology (2017)
Phase II Trial of Clofarabine in Combination with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Pediatric Patients with Refractory or Relapsed Acute Leukemia
Authors: Neerav Shukla, Rachel Kobos, Thomas M. Renaud, Laurel Steinherz, Peter G Steinherz
Journal: Blood (2012)
miR-125b promotes MLL-AF9–driven murine acute myeloid leukemia involving a VEGFA-mediated non–cell-intrinsic mechanism
Authors: Jun Liu, Bo Guo, Zhuo Chen, Nayi Wang, Michelina Iacovino, Jijun Cheng, Christine Roden, Wen Pan, Sajid Khan, Suning Chen, Michael Kyba, Rong Fan, Shangqin Guo, Jun Lu
Journal: Blood (2017)
Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.
Authors: Mathias Witzens-Harig, Dirk Hose, Simone Jünger, Christina Pfirschke, Nisit Khandelwal, Anja Seckinger, Heinke Conrad, Bettina Brackertz, Thierry Reme, Brigittte Gückel, Tobias Meissner, Michael Hundemer, Anthony D Ho, Jean-Francois Rossi, Kai Neben, Helga Bernhard, Hartmut Goldschmidt, Bernard Klein, Philipp Beckhove
Journal: Blood (2012)
IDH1/2, TET2 and DNMT3A Mutations Are Not Mutually Exclusive in Secondary Acute Myeloid Leukemias,
Authors: Olivier Kosmider, Olivier LaRochelle, Marie-Magdelaine Coude, Veronique Mansat-De Mas, Eric Delabesse, Pascale Cornillet-Lefebvre, Odile Blanchet, Christian Recher, Alain Delmer, Sophie Raynaud, Catherine Lacombe, Olivier Bernard, Norbert Ifrah, Francois Dreyfus, Michaela Fontenay
Journal: Blood (2011)
Complete mucosal repair after endoscopic submucosal enucleation of a gastric submucosal tumor assisted by the clip-with-line method
Authors: Yu-qi He, Ai-qin Li, Jian-qiu Sheng, Dong-liang Yu, Kuang-I Fu
Journal: Endoscopy (2017)

Deep ulcers and even perforations can occur after endoscopic submucosal enucleation (ESE) of gastrointestinal submucosal tumors (SMTs), as most SMTs arise from the muscularis propria layer. If SMTs can be removed by ESE without damaging the overlying normal mucosa, the defects can be completely closed with the remaining normal mucosa. Recently, countertraction has been reported to facilitate resection of gastrointestinal SMTs [1]. In this report, we describe how to use a clip-with-line (CWL) method to facilitate enucleation of an SMT, with the entire overlying normal mucosa preserved to close the defect completely after ESE.
P2.01-030 Prognostic Impact of Stathmin1 Expression in Patients with Non-Small Lung Cancer
Authors: Kimihiro Shimizu, Toshiteru Nagashima, Yoichi Ohtaki, Kai Obayashi, Seshiru Nakazawa, Yoko Azuma, Misaki Iijima, Takayuki Kosaka, Toshiki Yajima, Akira Mogi, Hiroyuki Kuwano
Journal: Journal of Thoracic Oncology (2017)
Refining the molecular organization of the cardiac intercalated disc
Authors: Sarah H. Vermij, Hugues Abriel, Toon A. B. van Veen
Journal: Cardiovascular Research (2017)

This review presents an extensively integrated model of the cardiac intercalated disc (ID), a highly orchestrated structure that connects adjacent cardiomyocytes. Classically, three main structures are distinguished: gap junctions (GJs) metabolically and electrically connect cytoplasm of adjacent cardiomyocytes; adherens junctions (AJs) connect the actin cytoskeleton of adjacent cells; and desmosomes function as cell anchors and connect intermediate filaments. Furthermore, ion channels reside in the ID. Mutations in ID proteins have been associated with cardiac arrhythmias such as Brugada syndrome and arrhythmogenic cardiomyopathy. However, rather than being independent, all ID components work together intensively by multifunctional proteins such as ZO-1, Ankyrin G, and β-catenin, integrating mechanical and electrical functions. GJs form a plaque surrounded by the perinexus in which free connexons reside; the connexome integrates NaV channels, the desmosome and GJs; and the area composita hosts AJs and desmosomes, also integrated as adhering junctions. Furthermore, the transitional junction connects sarcomeres to the plasma membrane. Lastly, this review integrates all these findings in comprehensible figures, illustrating the interdependencies of ID proteins.
P2.01-057 Association of Tumor Infiltrating Lymphocytes Quantification with EGFR Mutations in Completely Resected Stage IIIA(N2) Lung Adenocarcinoma
Authors: Wen Feng, Xiaolong Fu, Xuwei Cai, Qin Zhang, Yuan Li, Lei Shen
Journal: Journal of Thoracic Oncology (2017)
Abstract B30: Inhibition of eIF4E/MNK axis by novel MNKDAs reduces breast cancer tumor growth, migration, invasion and metastasis
Authors: Senthilmurugan Ramalingam, Lalji Gediya, Vidya Ramamurthy, Yong Choi, Rena Lapidus, Njar Vincent
Journal: Clinical Cancer Research (2017)

Abstract Triple-negative breast cancer (TNBC) represents a molecularly heterogeneous subgrouping of high-risk breast tumors characterized by aggressive behavior, poor prognosis and lack of targeted therapeutic options. The translation initiation factor eIF4E, an oncogene essential for cap-dependent translation of specific mRNAs critical for cell division, cell survival, angiogenesis, and metastasis is commonly overexpressed in primary breast cancers including TNBC. eIF4E therapeutic targeting is considered novel and significant because tumor cells specifically overexpress eIF4E and develop an oncogene addiction to eIF4E, rendering the cells vulnerable to eIF4E inhibition, whereas normal cells are relatively insensitive. Phosphorylation of eIF4E at serine-209 is critical for the oncogenic activity of eIF4E, and it has been suggested that chemical compounds that prevent the phosphorylation of eIF4E could act as effective anticancer drugs. Herein, we report that a novel inhibitor of peIF4E function (Novel Retinamides, NRs), safely and potently suppresses breast tumor formation. Administration of novel retinamides (mnk degrading agents: MNKDAs) blocked the growth of primary breast tumors in MDA-MB-231 xenograft model, TNBC patient derived xenografts (PDX), and reduced the development of lung metastases in an invasive model. Mechanistically, NRs resulted in the degradation of MNKs (MNK1 and MNK2), a key kinase chiefly responsible for phosphorylating and activating eIF4E. This in turn hampered peIF4E involved translation initiation and activation of genes associated with cell proliferation and survival. Furthermore, MNK degradation by NRs also suppressed epithelial-to-mesenchymal transition, a process crucial for metastasis as evident by increased expression of E-cadherin and reduced expression of N-cadherin, fibronectin and vimentin; snail, slug, twist, fibronectin, claudin, lamin, TCF/ZEB-1, beta catenin, MMPs and vimentin. Taken together, the preclinical evidence of tumor regression and metastasis in TNBC models suggest that NRs offers considerable promise as new therapeutic candidate to target TNBC and metastatic breast cancer. Citation Format: Senthilmurugan Ramalingam, Lalji Gediya, Vidya Ramamurthy, Yong Choi, Rena Lapidus, Njar Vincent. Inhibition of eIF4E/MNK axis by novel MNKDAs reduces breast cancer tumor growth, migration, invasion and metastasis. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr B30.